These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 17255829

  • 21. Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an alpha4 integrin inhibitor.
    Wehner NG, Shopp G, Osterburg I, Fuchs A, Buse E, Clarke J.
    Birth Defects Res B Dev Reprod Toxicol; 2009 Apr; 86(2):144-56. PubMed ID: 19283860
    [Abstract] [Full Text] [Related]

  • 22. Effects of natalizumab, an alpha4 integrin inhibitor, on the development of Hartley guinea pigs.
    Wehner NG, Shopp G, Rocca MS, Clarke J.
    Birth Defects Res B Dev Reprod Toxicol; 2009 Apr; 86(2):98-107. PubMed ID: 19294679
    [Abstract] [Full Text] [Related]

  • 23. Natalizumab for the treatment of Crohn's disease.
    Bickston SJ, Muniyappa K.
    Expert Rev Clin Immunol; 2010 Jul; 6(4):513-9. PubMed ID: 20594122
    [Abstract] [Full Text] [Related]

  • 24. Natalizumab: a promising treatment for Crohn's disease.
    Colombel JF, Peyrin-Biroulet L.
    Expert Rev Clin Immunol; 2006 Sep; 2(5):677-89. PubMed ID: 20477624
    [Abstract] [Full Text] [Related]

  • 25. Health-related quality of life in multiple sclerosis: effects of natalizumab.
    Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, Galetta SL, Giovannoni G, Havrdova E, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, AFFIRM and SENTINEL Investigators.
    Ann Neurol; 2007 Oct; 62(4):335-46. PubMed ID: 17696126
    [Abstract] [Full Text] [Related]

  • 26. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R, Lorenz V, Korak-Leiter M, Kager I, Sittl R.
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [Abstract] [Full Text] [Related]

  • 27. [Long-term outcome of infliximab therapy in pediatric Crohn disease].
    Wanty C, Stephenne X, Sokal E, Smets F.
    Arch Pediatr; 2011 Aug; 18(8):863-9. PubMed ID: 21723101
    [Abstract] [Full Text] [Related]

  • 28. Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an alpha4 integrin inhibitor.
    Wehner NG, Shopp G, Oneda S, Clarke J.
    Birth Defects Res B Dev Reprod Toxicol; 2009 Apr; 86(2):117-30. PubMed ID: 19278014
    [Abstract] [Full Text] [Related]

  • 29. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis.
    Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, Woo P, Nishimoto N, Yoshizaki K, Kishimoto T.
    Arthritis Rheum; 2005 Mar; 52(3):818-25. PubMed ID: 15751095
    [Abstract] [Full Text] [Related]

  • 30. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease.
    Turner D, Grossman AB, Rosh J, Kugathasan S, Gilman AR, Baldassano R, Griffiths AM.
    Am J Gastroenterol; 2007 Dec; 102(12):2804-12; quiz 2803, 2813. PubMed ID: 18042110
    [Abstract] [Full Text] [Related]

  • 31. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.
    Gordon FH, Lai CW, Hamilton MI, Allison MC, Srivastava ED, Fouweather MG, Donoghue S, Greenlees C, Subhani J, Amlot PL, Pounder RE.
    Gastroenterology; 2001 Aug; 121(2):268-74. PubMed ID: 11487536
    [Abstract] [Full Text] [Related]

  • 32. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease.
    Reinisch W, Panés J, Lémann M, Schreiber S, Feagan B, Schmidt S, Sturniolo GC, Mikhailova T, Alexeeva O, Sanna L, Haas T, Korom S, Mayer H.
    Am J Gastroenterol; 2008 Sep; 103(9):2284-92. PubMed ID: 18671816
    [Abstract] [Full Text] [Related]

  • 33. 12-month follow-up after successful infliximab therapy in pediatric crohn disease.
    Wynands J, Belbouab R, Candon S, Talbotec C, Mougenot JF, Chatenoud L, Schmitz J, Cézard JP, Goulet O, Hugot JP, Ruemmele FM.
    J Pediatr Gastroenterol Nutr; 2008 Mar; 46(3):293-8. PubMed ID: 18376247
    [Abstract] [Full Text] [Related]

  • 34. Natalizumab: new drug. Multiple sclerosis: risky market approval.
    Prescrire Int; 2008 Feb; 17(93):7-10. PubMed ID: 18354844
    [Abstract] [Full Text] [Related]

  • 35. Methotrexate treatment in pediatric Crohn disease patients intolerant or resistant to purine analogues.
    Weiss B, Lerner A, Shapiro R, Broide E, Levine A, Fradkin A, Bujanover Y.
    J Pediatr Gastroenterol Nutr; 2009 May; 48(5):526-30. PubMed ID: 19412004
    [Abstract] [Full Text] [Related]

  • 36. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?
    Verbeeck J, Van Assche G, Ryding J, Wollants E, Rans K, Vermeire S, Pourkarim MR, Noman M, Dillner J, Van Ranst M, Rutgeerts P.
    Gut; 2008 Oct; 57(10):1393-7. PubMed ID: 18436577
    [Abstract] [Full Text] [Related]

  • 37. Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease:the role of natalizumab.
    Ghosh S.
    Expert Opin Biol Ther; 2003 Sep; 3(6):995-1000. PubMed ID: 12943458
    [Abstract] [Full Text] [Related]

  • 38. [Natalizumab in the treatment of multiple sclerosis].
    Horga A, Horga de la Parte JF.
    Rev Neurol; 2003 Sep; 45(5):293-303. PubMed ID: 17876741
    [Abstract] [Full Text] [Related]

  • 39. Role of methotrexate in the management of Crohn disease.
    Ravikumara M, Hinsberger A, Spray CH.
    J Pediatr Gastroenterol Nutr; 2007 Apr; 44(4):427-30. PubMed ID: 17414138
    [Abstract] [Full Text] [Related]

  • 40. Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study.
    Chebli JM, Gaburri PD, De Souza AF, Pinto AL, Chebli LA, Felga GE, Forn CG, Pimentel CF.
    J Gastroenterol Hepatol; 2007 Feb; 22(2):268-74. PubMed ID: 17295882
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.